1-4 of 4
Zhi Hua Li, MD
Close
Sort by
Journal Articles

Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium

Suzanne Trudel, MD, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Annette E Hay, MB ChB, Olena Kis, PhD, Signy Chow, MD FRCPC, Zhi Hua Li, MD, Ellen Nong Wei, MSc, Lisa Wang, PhD, Christine Tran, Smitha Udagani, Chantale Blattler, Trevor J. Pugh, PhD, Helen X Chen, MD, Amit Oza, MD
Journal: Blood
Blood (2016) 128 (22): 4526.
https://doi.org/10.1182/blood.V128.22.4526.4526
Published: 2016
Journal Articles

Pre-Clinical Evaluation of a Small Molecule Inhibitor of CDK1 as Potential Therapy for MYC Expressing Mutiple Myeloma Tumors

Seda Zeng, Zhi Hua Li, MD, Marta Chesi, Chungyee Leung-Hagesteijn, MSc, Sheng-ben Liang, PhD, P. Leif Bergsagel, MD, Suzanne Trudel, MD
Journal: Blood
Blood (2008) 112 (11): 3667.
https://doi.org/10.1182/blood.V112.11.3667.3667
Published: 2008
Journal Articles

Potentiated Phospho-Protein Network Profiling of Multiple Myeloma Cell Lines and Primary Patient Samples by Multi-Parameter Flow Cytometry.

Zhi Hua Li, MD, Peter Leif Bergsagel, MD, Sue Chow, David Hedley, MD, Suzanne Trudel, MD
Journal: Blood
Blood (2007) 110 (11): 1505.
https://doi.org/10.1182/blood.V110.11.1505.1505
Published: 2007
Journal Articles

Evaluation of XL999, a Potent Inhibitor of FGFR3, for the Potential Treatment of t(4;14) Positive Multiple Myeloma.

Suzanne Trudel, MD, Xiu Zhi Yang, MD, Zhi Hua Li, MD, Sheng-ben Liang, PhD, Dana T. Aftab, PhD
Journal: Blood
Blood (2007) 110 (11): 2515.
https://doi.org/10.1182/blood.V110.11.2515.2515
Published: 2007